

Contents

List of Contributors	xiii
Preface	xv

1. The Spectrum of Rheumatic Diseases

Estefanía Calle, José A. Gómez-Puerta

1. Introduction	1
2. Systemic Autoimmune Diseases	3
2.1 Systemic Lupus Erythematosus	3
2.2 Rheumatoid Arthritis	3
2.3 Systemic Sclerosis	4
2.4 Idiopathic Inflammatory Myopathies	5
2.5 Antiphospholipid Syndrome	6
3. Autoinflammatory Diseases	7
4. Metabolic Diseases	8
4.1 Osteoporosis	8
4.2 Crystal Deposition Disease	9
4.3 Gout	9
5. Degenerative Diseases	10
5.1 Osteoarthritis	10
6. Conclusions	10
Keypoints	11
References	11

2. Comorbidities in Patients With Rheumatic Disease

Helga Radner

1. Introduction	15
1.1 The Concepts of Comorbidity and Multimorbidity	16
1.2 Prevalence of Multimorbidity in Rheumatic Conditions	16
2. Assessment of Comorbid Conditions	18
3. Impact of Comorbidities on Important Outcomes	18
3.1 Mortality	18
3.2 Health Economic Implications	21
3.3 Disease-Related Outcomes	21
3.4 Outcomes Related to Surgery	22
4. Distinct Comorbid Conditions	23
4.1 Cardiovascular Disease	23

4.2	Pulmonary Disease	24
4.3	Malignancies	25
4.4	Gastrointestinal Disease	27
4.5	Infections	28
4.6	Osteoporosis	28
4.7	Depression	29
5.	Conclusion	29
	Key Points	29
	List of Acronyms and Abbreviations	29
	References	30
3.	Drugs Used in Rheumatic Disease	
	<i>Ivan Padjen</i>	
1.	Introduction	39
2.	Nonsteroidal Antiinflammatory Drugs	40
3.	Glucocorticoids	42
4.	Immunosuppressants/Immunomodulators and Disease-Modifying Antirheumatic Drugs	45
4.1	Nonbiological Agents	45
4.2	Biologicals	54
5.	Colchicine	63
6.	Urate-Lowering Agents	64
7.	Conclusion	65
	Key Points	65
	List of Acronyms and Abbreviations	66
	Dedication	66
	References	67
4.	Essential and Optional Drugs for Rheumatic Diseases	
	<i>Martin Aringer</i>	
1.	Rheumatoid Arthritis and Spondylarthritides	78
2.	Giant Cell Arteritis and Polymyalgia Rheumatica	78
3.	Vasculitides	79
4.	Connective Tissue Diseases	80
5.	Basic Laboratory Assessment	81
6.	Glucocorticoids	81
7.	Nonsteroidal Anti-inflammatory Drugs	82
8.	Disease-Modifying Antirheumatic Drugs	82
9.	Antimalarials	83
10.	Conventional Synthetic Disease-Modifying Antirheumatic Drugs	83
10.1	Methotrexate	83
10.2	Sulfasalazine	83
10.3	Leflunomide	84

11. Biological Disease-Modifying Antirheumatic Drugs	84
11.1 Tumor Necrosis Factor Blockers (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab)	85
11.2 Interleukin-1 (Receptor) Blockade (Anakinra, Canakinumab)	86
11.3 Interleukin-6 (Receptor) Blockade (Sarilumab, Tocilizumab)	86
11.4 Interleukin-17 Blockade	87
11.5 Interleukin-12/23 and Interleukin-23 Blockade	87
11.6 Costimulation Blockade	87
11.7 B Cell Depletion	88
11.8 B Lymphocyte Stimulator/B Cell Activating Factor Blockade	88
12. Targeted Synthetic Disease-Modifying Antirheumatic Drugs	89
12.1 Janus Kinase Inhibition	89
12.2 Phosphodiesterase-4 Inhibition	89
13. Immunosuppressive Agents	89
13.1 Azathioprine	90
13.2 Mycophenolate Mofetil and Mycophenolic Acid	90
13.3 Cyclosporin A and Tacrolimus	90
13.4 Cyclophosphamide	91
14. Conclusions	91
Key Points	92
References	93

Monitoring of Disease and Treatment of Patients With Rheumatic Disease

Laure Gossec

1. Introduction	97
2. Properties of Monitoring Criteria	98
3. Monitoring Rheumatoid Arthritis	98
3.1 The Rheumatoid Arthritis Core Set	98
3.2 Joint Counts	99
3.3 Blood Tests	99
3.4 Patient-Reported Outcomes in Rheumatoid Arthritis	100
3.5 Imaging Criteria	103
3.6 Composite Scores	104
4. Monitoring Axial Spondyloarthritis	106
4.1 The Axial Spondyloarthritis Core Set	106
4.2 Clinical Examination in Axial Spondyloarthritis	106
4.3 Patient-Reported Outcomes in Axial Spondyloarthritis: Single Questions	107
4.4 Questionnaires in Axial Spondyloarthritis	108
4.5 Composite Patient-Reported Outcomes	109
4.6 Monitoring of Imaging in Axial Spondyloarthritis	110
4.7 Composite Scores in Axial Spondyloarthritis	111

5.	Monitoring Psoriatic Arthritis	111
5.1	The Core Set in Psoriatic Arthritis	112
5.2	Physical Examination of Musculoskeletal Disease Activity	113
5.3	Domains of Health Important for People Living With Psoriatic Arthritis and Specific Patient-Reported Outcomes	113
5.4	Widely Used, Nonspecific Patient-Reported Outcomes in Psoriatic Arthritis	117
5.5	Biology and Imaging	118
5.6	Composite Scores in Psoriatic Arthritis	118
6.	Monitoring Treatments	119
7.	Conclusion	119
	Key Points	119
	References	120
6.	Surgical Intervention for Rheumatoid Arthritis and Complication Risks	
	<i>Marcus Lee, David George, Suan Khor, Michael Elvey, Abbas Rashid</i>	
1.	Introduction	127
2.	General Concepts	128
2.1	The Operative Sequence	128
2.2	Indications and Contraindications for Surgery	129
2.3	Perioperative Management	129
3.	Surgical Intervention by Region	130
3.1	The Spine	130
3.2	The Upper Limb	134
3.3	The Lower Limb	146
4.	Conclusions	153
	Key Points	153
	List of Acronyms and Abbreviations	154
	References	155
7.	Conventional and Biological DMARDs in Systemic Rheumatic Diseases: Perioperative Risk/Benefit Management	
	<i>Fabiola Atzeni, Francesco Caso, Luisa Costa, Piercarlo Sarzi-Puttini, Ignazio F. Masala</i>	
1.	Introduction	161
2.	Conventional Synthetic Disease-Modifying Antirheumatic Drugs	162
2.1	Methotrexate	162
2.2	Recommendations	165
2.3	Conventional Synthetic Disease-Modifying Antirheumatic Drugs Other Than Methotrexate	166
2.4	Recommendations	168
3.	Biological Disease-Modifying Antirheumatic Drugs	168
3.1	Anti-TNF Drugs	168
3.2	Recommendations	172

3.3	Tocilizumab	172
3.4	Abatacept	173
3.5	Rituximab	173
3.6	Ustekinumab	173
3.7	Recommendations	174
4.	Conclusions	174
4.1	Recommendations	174
	Key Points	175
	References	176
8.	The Relevance of Preoperative Education Among Healthcare Providers, Family Caregivers, and Patients With Systemic Rheumatic Diseases	
	<i>Kirsten R. Ambrose, Fabiola Atzeni</i>	
1.	Introduction	183
2.	Making the Case for Preoperative Education	184
3.	Patient-Centered Approach to Preoperative Shared Decision-Making and Education	186
3.1	Shared Decision-Making Among Patients and Providers	187
3.2	Multidisciplinary Teams and Coordinated Care	188
3.3	Role of Nurses in Patient-Centered Care and Education	189
3.4	Use of Decision Aids	189
4.	Preoperative Patient Education Promotes Immediate and Long-Term Health Outcomes	190
4.1	Education About the Procedure, Hospital Experience, and Post-operative Care	190
4.2	Emotional Well-Being and Psychosocial Support	191
4.3	Self-Management and Family Care Provision	191
4.4	Physical Activity for Disease Management and Fitness for Surgery	192
4.5	Smoking Cessation Reduces Disease Activity and Risk of Surgical Complications	194
4.6	Drug Use and Possible Adverse Events During Peri and Post-operative Period	195
5.	Conclusions	196
	Key Points	196
	List of Acronyms and Abbreviations	197
	References	197